Calidi Biotherapeutics, Inc. (CLDI)

Several events have impacted Calidi Biotherapeutics' stock in the past six months. On January 28, 2026, the company provided a corporate update and outlined key value drivers for 2026. On November 17, 2025, Calidi Biotherapeutics announced an exclusive live investor webinar and Q&A session. On November 13, 2025, the company reported its Third Quarter 2025 Financial Results, which led to a stock decline. On November 10, 2025, Calidi Biotherapeutics presented new data on CLD-401 at the 2025 SITC Annual Meeting and hosted its first Investor Day. On August 8, 2025, the company reported its Second Quarter 2025 Financial Results, showing a net loss, and CLD-201 received FDA Fast Track Designation. The stock decreased by 26.3% from the beginning of 2026 to February 3, 2026, and has experienced a significant decrease of 94.95% over the last year.

The demand for Calidi Biotherapeutics' products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by disease incidence, clinical trial progression, regulatory approvals, and the medical need for effective cancer treatments, rather than seasonal patterns.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies and genetic medicines for cancer and infectious diseases. The company's core business involves using the body's immune system to treat cancers, utilizing proprietary platforms to deliver oncolytic viruses that selectively target and destroy cancer cells while stimulating an immune response. Key products and platforms include the RedTail Platform (CLD-401), NeuroNova (CLD-101), SuperNova (CLD-201), RTNova Platform, CLD-301, CLD-400, CB-012, and CB-013.

Calidi Biotherapeutics, Inc. is headquartered in San Diego, California, and its development activities are primarily focused within the United States.

Calidi Biotherapeutics' brand reputation is influenced by its clinical development progress, scientific advancements, and regulatory milestones. Positive events like FDA Fast Track Designation for CLD-201 and promising preclinical data on CLD-401 contribute positively. The company's focus on unmet medical needs in cancer treatment also supports its reputation, while stock price declines could reflect investor sentiment and indirectly impact its broader reputation.

The ownership structure of Calidi Biotherapeutics stock includes institutional, retail, and individual investors. Institutional investors hold approximately 0.70% to 1.05% of the stock, while insiders own between 5.09% and 6.70%. Public companies and individual investors collectively hold a substantial portion, ranging from 0.36% to 93.86%. Major institutional shareholders include HighTower Advisors, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Belpointe Asset Management LLC, Warberg Asset Management LLC, Rs Crum Inc., Farther Finance Advisors, LLC, UBS Group AG, Highbridge Capital Management Llc, and Finepoint Capital LP.